Canary Capital has made history with the presentation to the U.S. Securities and Exchange Commission (SEC) of the first exchange-traded fund (ETF) of Injective. This presentation has driven the price of INJ in a meteoric rise, with a gain of almost 5% in the last 24 hours.
